Evaluation of s100β, NSE and GFAP Levels in Renal Transplantation

CompletedOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

August 15, 2019

Primary Completion Date

December 15, 2020

Study Completion Date

January 15, 2021

Conditions
Kidney Transplant; ComplicationsNeurologic ManifestationsUremic Encephalopathy
Interventions
DIAGNOSTIC_TEST

S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)

S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.

Trial Locations (1)

07070

Akdeniz University Hospital, Antalya

All Listed Sponsors
lead

Akdeniz University

OTHER

NCT04042272 - Evaluation of s100β, NSE and GFAP Levels in Renal Transplantation | Biotech Hunter | Biotech Hunter